Combined modalities for the prevention of ovarian hyperstimulation syndrome following an excessive response to stimulation

References

• Navot D, Bergh PA, Laufer N. Ovarian hyperstimulation syndrome in novel reproductive technologies: prevention and treatment. Fertil Steril 1992;58:249–61.
   PubMed Web of Science ®Google Scholar
• Luke B, Brown MB, Morbeck DE, et al. Factors associated with ovarian hyperstimulation syndrome (OHSS) and its effect on assisted reproductive technology (ART) treatment and outcome. Fertil Steril 2010;94:1399–404.
   PubMed Web of Science ®Google Scholar
• Aramwit P, Pruksananonda K, Kasettratat N, Jammeechai K. Risk factors for ovarian hyperstimulation syndrome in Thai patients using gonadotropins for in vitro fertilization. Am J Health Syst Pharm 2008;65:1148–53.
   PubMed Web of Science ®Google Scholar
• Danninger B, Brunner M, Obruca A, Feichtinger W. Prediction of ovarian hyperstimulation syndrome by ultrasound volumetric assessment [corrected] of baseline ovarian volume prior to stimulation. Hum Reprod 1996;11:1597–9.
   PubMed Web of Science ®Google Scholar
• Seyhan A, Ata B, Polat M, et al. Severe early ovarian hyperstimulation syndrome following GnRH agonist trigger with the addition of 1500 IU hCG. Hum Reprod 2013;28:2522–8.
   PubMed Web of Science ®Google Scholar
• Al-Inany HG, Youssef MA, Ayeleke RO, et al. Gonadotrophin-releasing hormone antagonists for assisted reproductive technology. Cochrane Database Syst Rev 2016;4:Cd001750.
   PubMedGoogle Scholar
• Varnagy A, Bodis J, Manfai Z, et al. Low-dose aspirin therapy to prevent ovarian hyperstimulation syndrome. Fertil Steril 2010;93:2281–4.
   PubMed Web of Science ®Google Scholar
• Revelli A, Dolfin E, Gennarelli G, et al. Low-dose acetylsalicylic acid plus prednisolone as an adjuvant treatment in IVF: a prospective, randomized study. Fertil Steril 2008;90:1685–91.
   PubMed Web of Science ®Google Scholar
• Palomba S, Falbo A, La Sala GB. Effects of metformin in women with polycystic ovary syndrome treated with gonadotrophins for in vitro fertilisation and intracytoplasmic sperm injection cycles: a systematic review and meta-analysis of randomised controlled trials. BJOG 2013;120:267–76.
   PubMed Web of Science ®Google Scholar
• Tannus S, Burke Y, McCartney CR, Kol S. GnRH-agonist triggering for final oocyte maturation in GnRH-antagonist IVF cycles induces decreased LH pulse rate and amplitude in early luteal phase: a possible luteolysis mechanism. Gynecolo Endocrinol 2017;33:741–5.
   PubMed Web of Science ®Google Scholar
• Youssef MA, Van der Veen F, Al-Inany HG, et al. Gonadotropin-releasing hormone agonist versus HCG for oocyte triggering in antagonist-assisted reproductive technology. Cochrane Database Syst Rev 2014;Cd008046.
   PubMed Web of Science ®Google Scholar
• Humaidan P, Polyzos NP, Alsbjerg B, et al. GnRHa trigger and individualized luteal phase hCG support according to ovarian response to stimulation: two prospective randomized controlled multi-centre studies in IVF patients. Hum Reprod 2013;28:2511–21.
   PubMed Web of Science ®Google Scholar
• Castillo JC, Dolz M, Bienvenido E, et al. Cycles triggered with GnRH agonist: exploring low-dose HCG for luteal support. Reprod Biomed 2010;20:175–81.
   PubMed Web of Science ®Google Scholar
• Ata B, Seyhan A, Polat M, et al. Risk factors for ovarian hyperstimulation syndrome: relevance of the number of follicles, serum estradiol levels and the number of oocytes collected. Hum Reprod 2013;28:2595.
   PubMed Web of Science ®Google Scholar
• O’Neill KE, Senapati S, Maina I, et al. GnRH agonist with low-dose hCG (dual trigger) is associated with higher risk of severe ovarian hyperstimulation syndrome compared to GnRH agonist alone. J Assist Reprod Genet 2016;33:1175–84.
   PubMed Web of Science ®Google Scholar
• Engmann L, Siano L, Schmidt D, et al. GnRH agonist to induce oocyte maturation during IVF in patients at high risk of OHSS. Reprod Biomed Online 2006;13:639–44.
   PubMed Web of Science ®Google Scholar
• Iliodromiti S, Lan VT, Tuong HM, et al. Impact of GnRH agonist triggering and intensive luteal steroid support on live-birth rates and ovarian hyperstimulation syndrome: a retrospective cohort study. J Ovarian Res 2013;6:93.
   PubMed Web of Science ®Google Scholar
• Mahajan N, Gupta S, Sharma S, et al. Early onset ovarian hyperstimulation syndrome despite use of segmentation approach and ovarian hyperstimulation syndrome prophylaxis. J Hum Reprod Sci 2015;8:234–8.
   PubMedGoogle Scholar
• Gurbuz AS, Gode F, Ozcimen N, Isik AZ. Gonadotrophin-releasing hormone agonist trigger and freeze-all strategy does not prevent severe ovarian hyperstimulation syndrome: a report of three cases. Reprod Biomed Online 2014;29:541–4.
   PubMed Web of Science ®Google Scholar
• Gomez R, Gonzalez-Izquierdo M, Zimmermann RC, et al. Low-dose dopamine agonist administration blocks vascular endothelial growth factor (VEGF)-mediated vascular hyperpermeability without altering VEGF receptor 2-dependent luteal angiogenesis in a rat ovarian hyperstimulation model. Endocrinol 2006;147:5400–11.
   PubMed Web of Science ®Google Scholar
• Tang H, Mourad S, Zhai SD, Hart RJ. Dopamine agonists for preventing ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2016;11:Cd008605.
   PubMedGoogle Scholar
• Lainas GT, Kolibianakis EM, Sfontouris IA, et al. Pregnancy and neonatal outcomes following luteal GnRH antagonist administration in patients with severe early OHSS. Hum Reprod 2013;28:1929–42.
   PubMed Web of Science ®Google Scholar
• Asimakopoulos B, Nikolettos N, Nehls B, et al. Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures. Fertil Steril 2006;86:636–41.
   PubMed Web of Science ®Google Scholar
• Lainas GT, Kolibianakis EM, Sfontouris IA, et al. Outpatient management of severe early OHSS by administration of GnRH antagonist in the luteal phase: an observational cohort study. Reprod Biol Endocrinol 2012;10:69.
   PubMed Web of Science ®Google Scholar
• Fatemi HM, Popovic-Todorovic B, Humaidan P, et al. Severe ovarian hyperstimulation syndrome after gonadotropin-releasing hormone (GnRH) agonist trigger and “freeze-all” approach in GnRH antagonist protocol. Fertil Steril 2014;101:1008–11.
   PubMed Web of Science ®Google Scholar
• El-Khayat W, Elsadek M. Calcium infusion for the prevention of ovarian hyperstimulation syndrome: a double-blind randomized controlled trial. Fertil Steril 2015;103:101–5.
   PubMed Web of Science ®Google Scholar
• Gurgan T, Demirol A, Guven S, et al. Intravenous calcium infusion as a novel preventive therapy of ovarian hyperstimulation syndrome for patients with polycystic ovarian syndrome. Fertil Steril 2011;96:53–7.
   PubMed Web of Science ®Google Scholar
• Naredi N, Karunakaran S. Calcium gluconate infusion is as effective as the vascular endothelial growth factor antagonist cabergoline for the prevention of ovarian hyperstimulation syndrome. J Hum Reprod Sci 2013;6:248–52.
   PubMedGoogle Scholar